Forward Citations = 12

Loading Chart...

3 inventors (with patents filed for the assignee):

Carl Alexander Kamb (4 out of 7 patents)

Giordano Michael Caponigro (2 out of 2 patents)

Majid Abedi (1 out of 2 patents)

4 patents: Sort by Forward Citations

1. 6623922 - Methods for identifying, characterizing, and evolving cell-type specific CIS regulatory elements (2003-09-23),

2. 6582899 - Methods for identifying agents that cause a lethal phenotype, and agents thereof (2003-06-24),

3. 6579675 - Methods for identifying nucleic acid sequences encoding agents that effect cellular phenotypes (2003-06-17),

4. 6566057 - Methods and compositions for peptide libraries displayed on light-emitting scaffolds (2003-05-20),

Company Overview

Deltagen Proteomics, Inc. is a leading biotech company specializing in protein research and molecular diagnostics. With a focus on personalized medicine, we strive to develop innovative solutions for detecting and treating various diseases. Our state-of-the-art technology and expertise in proteomics allow us to deliver accurate and reliable results to our clients in the healthcare industry.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

4 Patents

#287 in Salt Lake City, UT

#778 in Utah

#60,671 in US

Salt Lake City, UT, United States of America

Deltagen Proteomics, Inc.

Forward Citations = 12

3 inventors:

Carl Alexander Kamb (4 out of 7 patents)

Giordano Michael Caponigro (2 out of 2 patents)

Majid Abedi (1 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Deltagen Proteomics, Inc.. Retrieved from https://idiyas.com/company/deltagen-proteomics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]